Type I Diabetes Clinical Trial
Official title:
Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan
This study will test dihydrotetrabenazine, or 11C-DTBZ, a radioactive tracer, as an imaging
agent in positron emission tomography (PET). That tracer may have the ability to
noninvasively measure beta cell, that is, -cell mass (BCM) in humans. For researchers hoping
to develop new treatments for diabetes mellitus, a method of measuring BCM is very important.
In this study, researchers will determine if patients with Type 1 diabetes mellitus, who have
almost no BCM, have much less pancreatic uptake of the tracer than do patients without
diabetes. Patients ages 18 and older may be eligible for this study. Three groups will be
studied: Participants who have Type 1 diabetes, those without diabetes, and those who have
been successfully treated with a transplant of the pancreas or pancreas and kidney
The study involves three sets of tests that can be done as an outpatient or after being
admitted to the hospital. Patients will undergo a medical history and procedures including
collection of blood (about 4 teaspoons), pregnancy test for women of childbearing age,
magnetic resonance imaging (MRI) scan, PET scan, and tests involving arginine and glucose.
Arginine is a substance that stimulates insulin release from the -cells. During the
procedure, two intravenous (IV) lines are placed into the arms, one to administer arginine
and the other to draw blood (about eight samples during 10 minutes). For the glucose test,
patients will drink a solution of dextrose, a sugar, and blood samples will be taken over 2
hours from the IV lines. Some patients experience nausea after drinking the solution. Within
48 hours of either test or both, patients will be placed in the PET scan machine and given an
injection of the radioactive material through an IV line. Blood samples of about one-half
teaspoon will be drawn before the procedure starts and again every 10 seconds for the first 2
minutes and at several intervals, up to 60 minutes. Finally, patients will also an MRI scan,
30 to 60 minutes long, of the abdomen. This test will be down within two weeks of the PET
scan. MRI uses a strong magnetic field and radio waves to obtain images of body organs and
tissues. During the scan, patients will be asked to lie still on a table that slides into the
tunnel of the scanner. They will be given earplugs, for the machine can be noisy. Patients
who have metal within their body that is not compatible with the MRI machine will be
withdrawn from the study.
Diabetes is a metabolic disorder in which pancreatic insulin producing B-cells (located in
cell clusters called the islets of Langerhans) no longer produce sufficient insulin to
maintain an individual's blood sugar concentration within the normal range. Insufficient
B-cell function can be caused by an autoimmune killing of the B-cells in type 1 diabetes
mellitus (T1DM), or by poorly understood mechanisms in type 2 diabetes mellitus (T2DM).
Regardless of the underlying cause, the development of new diabetes treatments is limited by
our current inability to objectively measure B-cell mass.
We propose testing a previously used clinical radioligand, dihydrotetrabenazine (DTBZ), as a
Positron Emission Tomography (PET) imaging agent for its ability to non-invasively measure
B-cell mass in humans. We will study 30 patients, 10 with T1DM, 10 with normal glucose
homeostasis, and 5 with a history of T1DM, but successfully restored glucose homeostasis
following whole pancreas transplantation. Prior to the PET scans, each patient will undergo
metabolic testing to characterize their glucose homeostasis and insulin producing capacity.
The pancreas will be initially identified in each patient with high-resolution magnetic
resonance imaging (MRI). Then, using anatomical landmarks identified by the MRI, the subject
will undergo DTBZ-PET imaging. We predict that the radioactivity signal in the pancreas from
the DTBZ-PET images will be significantly different between control subjects and T1DM
subjects. Further, we predict that the DTBZ-PET images obtained in individuals with
functioning pancreas allografts (and such patients have two pancreases- their native pancreas
and their pancreas allografts) will reveal signal intensities from the two glands that
correlates closely with each gland's insulin producing capacity. Should these studies suggest
DTBZ has merit as a beta cell imaging agent, we will expand the study to include patients
with T2DM.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05160142 -
Diabetes Inspired Culinary Education
|
Early Phase 1 | |
Withdrawn |
NCT05035368 -
Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT01928329 -
A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes
|
Phase 2 | |
Completed |
NCT02127762 -
The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT00999375 -
Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF)
|
Phase 2 | |
Completed |
NCT04279613 -
A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041
|
Phase 1 | |
Not yet recruiting |
NCT02117518 -
Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients
|
N/A | |
Withdrawn |
NCT01477476 -
Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes
|
Phase 2 | |
Terminated |
NCT01308437 -
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
|
Phase 3 | |
Terminated |
NCT01652911 -
A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT06242548 -
How Type I Diabetes Responds to Different Diets (Normoglucidic or Ketogenic) During Physical Activity at Altitude
|
N/A | |
Withdrawn |
NCT00361608 -
Monitoring of Nocturnal Hypoglycemia Using EarlySense Monitoring Device
|
N/A | |
Terminated |
NCT03653533 -
Evaluation of the Function "Stop Before Hypoglycemia" on External Insulin Pump
|
N/A | |
Completed |
NCT00340639 -
Management of Type 1 Diabetes Among Adolescents
|
N/A | |
Completed |
NCT02002130 -
The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes
|
Phase 1 | |
Completed |
NCT02634216 -
Effects of Capros in Patients With Type-1 Diabetes
|
N/A | |
Withdrawn |
NCT01623388 -
Epigenetic Modifications of Diabetes Mellitus Type I
|
N/A | |
Completed |
NCT02612493 -
Obesity and Metabolic Surgery in Patients With Type I Diabetes
|
N/A | |
Completed |
NCT01843114 -
Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects
|
N/A | |
Withdrawn |
NCT01398670 -
Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics
|
Phase 3 |